Crown Equity Holdings Inc. (OTCBB:CRWE) announced recently that it has launched its crwenewswire.fr website to provide news in France’s native language. Crown Equity Holdings Inc. had previously launched its German website crwenewswire.de and is launching its Canadian website crwenewswire.ca shortly.
“The new website is one step in many towards the company goal of expanding its footprint internationally, ” commented Kenneth Bosket, President and CEO of Crown Equity Holdings Inc. “Our goal for 2010 is to have all CRWE’s clients’ press releases, articles and news content published in every major financial country’s native language, as well as within cities of every state of our country,” stated Mr. Bosket.
Crown Equity Holdings Inc. is a consulting organization which provides and assists small business owners with the knowledge required in taking their company public, and has re-focused its primary vision with its aligned group of independent website divisions to providing media advertising services, as a worldwide online media advertising publisher, dedicated to the distribution of quality branding information, as well as search engine optimization for its clients.
The true beauty of Halloween is in the details. A sound in the distance you can barely make out, a passing glimpse you aren’t sure you really saw, a sudden cold breeze you didn’t expect. These are just some of the subtleties that give the season its sense of fright and fun, and they are all reflected in the latest collection from American Greetings Corporation (NYSE:AM), which combines traditions and innovation to offer an appropriately sweet variety.
Shoppers looking to share the Halloween spirit need look no further than the card aisle this year to find everything they could desire. A playful mix of dark shades and bedeviling designs enliven classic characters, and the fun combination may just cause a bit of nostalgia for parents as they watch their children enjoy the same traditions they once did.
One new collection this Halloween sure to inspire some nostalgic smiles is Flipbook�. Similar to the homemade flipbook “cartoons” of youth, these cards offer both trick and treat.
Each Flipbook greeting features an entertaining animation that is produced by simply pulling panels to reveal a surprising design. From a cute black cat popping out of a pumpkin to a witch in flight, the scenes are fun to produce over and over again and sure to be enjoyed by any recipient.
American Safety Insurance Holdings, Ltd. (NYSE: ASI) announced recently that Stephen R. Crim, President and Chief Executive Officer, and Mark W. Haushill, Chief Financial Officer, will present at the Keefe, Bruyette & Woods 2010 Insurance Conference at the Waldorf-Astoria Hotel in New York City on Wednesday, September 8, 2010, at 11:25 a.m. EDT.
The presentation will be available live via webcast on our website, www.amsafety.com or http://cc.talkpoint.com/confcastsignup/keef001/090710a_me.asp, and will be archived for replay up to 60 days after the conference. For general information on accessing the webcast, please refer to KBW�s website at www.kbw.com.
Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT), a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has designated AMT-080, a gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug. In October 2009, the Committee for Orphan Medical Products of the European Medicines Agency granted AMT-080 orphan designation for the same indication in the European Union.
AMT has shown efficacy in studies of a preclinical model of DMD. These proof of concept studies demonstrated that AMT’s technology resulted in functional dystrophin synthesis in both the heart and skeletal muscles, leading to the prevention of muscular dystrophy. These data are strengthened by a study in which this gene therapy approach was shown to successfully restore dystrophin activity in diseased human muscle cells obtained from biopsies of DMD patients. A Phase I/II clinical trial is scheduled to start by the end of 2012.
AMT has received an Innovation Credit of up to EUR 4 million from the Dutch government to support the development of AMT’s gene therapy treatment for Duchenne Muscular Dystrophy (DMD). The credit is granted by SenterNovem, an agency of the Dutch Ministry of Economic affairs.
No comments:
Post a Comment